On July 22, 2022, FDA announced the availability of a proposed rule, that is intended to minimize the impact of FDA running out of ten-digit national drug codes (NDCs) by adopting a single, uniform 12-digit format for FDA-assigned NDCs.
What is the NDC and what changes is the FDA proposing?
The NDC is the FDA standard for uniquely identifying drugs marketed in the United States. FDA is proposing:
- to change the NDC to 12 digits in length with three distinct and consistent segments and one uniform format.
- to revise the drug product barcode label requirements.
How would it help if the proposed rule on revising the NDC is finalised?
Because the Agency is running out of 10-digit NDCs, this rule, if finalized, would provide certainty and predictability to stakeholders by selecting a prespecified date for an NDC change.
One expected benefit of the proposed rule, if finalized, is that the proposed standardized format would facilitate the adoption of a single NDC format by all stakeholders. Such an adoption would eliminate the need to convert NDCs from one of FDA’s prescribed formats to a different standardized format used by other sectors of the healthcare industry (e.g., healthcare providers and payors).
What are the provisions under the proposed rule?
- FDA is proposing to amend US regulations on foreign and domestic establishment registration and listing for drugs, including biological products and animal drugs.
- This proposed rule will affect drug products that are required to be listed under section 510 of the FD&C Act and 21 CFR part 207.
- Once effective, existing 10-digit NDCs will be required to convert to the new uniform 12-digit NDC format and new NDCs will be assigned in the 12-digit format.
1) Format of national drug codes
Under the proposed rule: the NDC would remain a three-segment numerical code consisting of:
- the labeler code,
- the product code, and
- the package code.
Specifically, FDA is proposing that the labeler code would be six digits in length, the product code would be four digits in length, and the package code would be two digits in length, a universal 6-4-2 format.
2) The proposed approach
i) Effective date
FDA is proposing an effective date five years after the publication of the final rule to allow stakeholders time to develop and implement changes to their systems.
ii) Effective Date associated activities:
- On the effective date identified in the final rule, FDA would begin assigning new NDCs in the uniform 12-digit format.
- Certain stakeholders that use FDA-assigned NDCs would need to have systems capable of handling the new, uniform, 12-digit NDC on the effective date of the final rule.
- Drug listing files submitted on or after this date would be required to use the 12-digit NDC.
To reduce the burden on registrants, FDA does not intend to require resubmission of all existing drug listing files. Instead, FDA intends to convert existing NDCs on its own on the effective date by adding leading zeros to the appropriate segments.
iii) Transition period
- A transition period for labeling will last three years after the effective date.
- FDA encourages manufacturers and distributors to include 12-digit NDCs on their drug labeling as soon as possible after the effective date.
- However, to aid with the transition, for a period of three years following the effective date, FDA does not intend to object to the continued use of 10-digit NDCs on the labeling of products that were assigned a 10-digit NDC prior to the effective date.
- FDA intends to mitigate the risk of medication error and confusion during the transition period by maintaining and publishing both the 10-digit and 12-digit NDC formats for specific drugs. This will provide stakeholders with a resource to confirm the identity of the drug in the event of any confusion.
3) Labeling
- Product labeling that includes a product’s 10-digit NDC would need to be updated to convert the 10-digit NDC to the standard 12-digit format.
- FDA is:
- also proposing to revise the drug barcode label requirements to allow the use of either linear or nonlinear barcodes, so long as the barcode meets the prescribed standards.
- considering whether to further revise 21 CFR 201.25(c) to accommodate potential advances in technologies and standards development by allowing the use of unspecified automatic identification and data capture (AIDC) formats other than linear or non-linear barcodes in the future without the need to revise the regulation again.
Source: FDA